Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CollPlant Biotechnologies (CLGN) Gross Margin (2017 - 2025)

CollPlant Biotechnologies filings provide 9 years of Gross Margin readings, the most recent being 220.0% for Q4 2025.

  • On a quarterly basis, Gross Margin fell 15415.0% to 220.0% in Q4 2025 year-over-year; TTM through Dec 2025 was 295169.0%, a 29495347.0% decrease, with the full-year FY2025 number at 64.78%, up 28032.0% from a year prior.
  • Gross Margin hit 220.0% in Q4 2025 for CollPlant Biotechnologies, up from 249.35% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 93.96% in Q2 2023 to a low of 3910614.53% in Q2 2025.
  • Median Gross Margin over the past 5 years was 76.77% (2021), compared with a mean of 281421.08%.
  • Biggest five-year swings in Gross Margin: surged 142842923bps in 2022 and later crashed -391049926bps in 2025.
  • CollPlant Biotechnologies' Gross Margin stood at 76.77% in 2021, then soared by 91bps to 6.9% in 2022, then tumbled by -2199bps to 158.53% in 2023, then surged by 58bps to 65.85% in 2024, then plummeted by -234bps to 220.0% in 2025.
  • The last three reported values for Gross Margin were 220.0% (Q4 2025), 249.35% (Q3 2025), and 3910614.53% (Q2 2025) per Business Quant data.